Gilead to Acquire Tubulis in $3.15 Billion Deal to Strengthen Antibody-Drug Conjugate Pipeline
Munich, Germany: In a strategic move to expand its oncology portfolio, Gilead Sciences has announced plans to acquire Tubulis GmbH, a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs).
The deal, valued at $3.15 billion upfront, with up to $1.85 billion in additional milestone payments, marks a significant investment in targeted cancer therapies and reinforces Gilead’s ambitions in oncology.
Expanding the ADC Arsenal
Antibody-drug conjugates are an emerging class of cancer therapeutics designed to deliver potent drugs directly to tumor cells while minimizing damage to healthy tissues.
With this acquisition, Gilead gains access to Tubulis’ advanced ADC platform technologies, including its Tubutecan linker-payload system, which enables precise and stable delivery of cytotoxic agents to cancer cells.
The move builds on an existing collaboration between the two companies and positions Gilead to accelerate innovation in targeted cancer therapies.
Promising Pipeline Assets
A key highlight of the acquisition is TUB-040, Tubulis’ lead candidate:
- A NaPi2b-targeting ADC
- Currently in Phase 1b/2 trials
- Being developed for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC)
The deal also includes TUB-030, a 5T4-targeting ADC that has shown encouraging early clinical results across multiple solid tumors.
These assets are expected to complement Gilead’s existing oncology pipeline, which increasingly focuses on precision therapies for difficult-to-treat cancers.
Strategic Rationale
Gilead’s CEO emphasized that the acquisition represents a major step in building one of the company’s most diverse oncology pipelines to date.
By integrating Tubulis’ platform, Gilead aims to:
- Enhance target specificity of cancer therapies
- Expand payload diversity in ADC design
- Accelerate development of next-generation treatments
For Tubulis, the acquisition provides access to Gilead’s global development capabilities and commercialization infrastructure, potentially speeding the path from research to patient care.
A Growing Focus on Precision Oncology
The acquisition reflects a broader industry trend toward precision oncology, where treatments are tailored to specific tumor markers and biological pathways.
ADCs are at the forefront of this shift, combining the targeting ability of antibodies with the potency of chemotherapy agents. Advances in linker technologies—such as those developed by Tubulis—are critical to improving efficacy and safety.
Operational Integration
Following the completion of the deal, Tubulis will operate as a dedicated ADC research unit within Gilead. Its Munich site will serve as a central hub for ADC innovation, leveraging its integrated capabilities in discovery, manufacturing, and clinical development.
The transaction is expected to close in the second quarter of 2026, pending regulatory approvals and customary conditions.
Looking Ahead
As competition intensifies in the oncology space, strategic acquisitions like this highlight the importance of platform technologies in shaping the next generation of cancer treatments.
By combining Tubulis’ cutting-edge ADC innovations with its own development expertise, Gilead is positioning itself to deliver more effective, targeted therapies for patients with unmet medical needs.
Source: Tubulis & Gilead official announcement, April 2026
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
